Head-to-head · WeighScore
Fitish vs Goldspan Health
The verdict
Goldspan Health takes it — 68.2/100 to 60.9/100.
Goldspan Health grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Goldspan Health runs one plan per molecule with no tier ladder, bills every 28 days rather than monthly, and requires a lab panel it never prices.
We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.
Factor by factor
The same six graded dimensions, side by side. See the methodology.
The numbers
| Metric | Fitish | Goldspan Health |
|---|---|---|
| WeighScore | 60.9/100 | 68.2/100 |
| Grade | C | C |
| Scorecard rank | #332 | #161 |
| Semaglutide | $219/mo (compounded) | $229 per 28 days (a single plan; thirteen charges a year) |
| Tirzepatide | $339/mo (compounded) | $299 per 28 days (a single plan; thirteen charges a year) |
| Coverage | All 50 states | All 50 states plus Washington, D.C. |
| Brand-name access | Compounded only | Compounded only |
| Oral / sublingual | Yes | Yes |
Graded #332 · C
FDAWarning letter issued to FITISH in June 2026. See the FDA warning-letter database.
Strengths
- LegitScript certified
- Ships to all US states
- Price includes consult, shipping, and medication
- Injectable and oral tablet formats
- Microdosing option available
Where it loses points
- No physical address disclosed
- Broader wellness/beauty brand — GLP-1 is one product line
- Compounded only — no brand-name options
- FDA issued FITISH a warning letter in June 2026; the letter is public in FDA's warning-letter database
Graded #161 · C
Strengths
- One plan per molecule with no tier ladder to read, which removes the commonest source of a misquoted price
- Sublingual full-dose and microdose lines sit alongside the injections for readers who will not inject
- States its compounding class — dispensed by a pharmacy licensed under 503A or 503B — rather than leaving it unsaid
- Names a medical director and two clinical advisors by name and specialty
- A lab panel is genuinely required at 60 to 90 days and annually after that, which is stronger monitoring than most of this ranking asks for
Where it loses points
- The required lab panel is described as available at a low cost and its cost is stated nowhere on the site
- The hero says “/month”, the plan card says billed every 28 days and the order timeline says every four weeks — thirteen charges a year, not twelve
- “Pause, delay, or cancel at any time” on the storefront sits against a refund policy reading “all sales are final” and platform terms saying an order cannot be canceled once placed
- The tirzepatide sublingual microdose page lists compounded sublingual semaglutide microdose in its own inclusion list
- Clinicians are attributed to a partner platform while the storefront states it is not a medical practice
- No pharmacy is named, and Goldspan publishes no legal entity, address or governing law of its own
- Full-dose sublingual products exist on the catalog and are not linked from the site's own weight-loss page
Also worth a look
Neither is our top-graded pick — CoreAge Rx leads the scorecard
Across all 536 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.
Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.